Clinical Trial Protocol for PERFECT: A Randomised Controlled Trial Comparing the Efficiency and Tolerance of Transperineal Fusion Versus Transrectal Imaging-targeted Prostate Biopsies (CCAFU-PR1 Study).
Complications
Efficiency
Fusion biopsy
Prostate cancer
Transperineal
Transrectal
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
accepted:
02
09
2022
entrez:
11
10
2022
pubmed:
12
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
PERFECT is a multicentre randomised controlled clinical trial that evaluates the efficiency of fusion magnetic resonance imaging-targeted biopsies in the transperineal (TP) versus transrectal (TR) approach in terms of the detection of significant cancers. Our study builds on the hypothesis that the TP approach for prostate biopsies has at least the same diagnostic accuracy as the TR approach, with lower morbidity. Here, we describe the clinical protocol, study population, and primary and secondary outcomes.
Identifiants
pubmed: 36217451
doi: 10.1016/j.euros.2022.09.007
pii: S2666-1683(22)01907-3
pmc: PMC9547228
doi:
Types de publication
Journal Article
Langues
eng
Pagination
76-80Informations de copyright
© 2022 The Author(s).
Références
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):62-65
pubmed: 31932659
BJU Int. 2014 Sep;114(3):384-8
pubmed: 24612341
J Urol. 2021 Apr;205(4):1069-1074
pubmed: 33487007
Zhonghua Nan Ke Xue. 2014 Nov;20(11):1004-7
pubmed: 25577836
BJU Int. 2020 Jul;126(1):133-141
pubmed: 32232966
Clin Genitourin Cancer. 2019 Oct;17(5):e860-e870
pubmed: 31281065
Lancet Oncol. 2019 Jan;20(1):100-109
pubmed: 30470502
World J Surg Oncol. 2019 Feb 13;17(1):31
pubmed: 30760274
J Urol. 2020 Dec;204(6):1141-1149
pubmed: 32716687
BJU Int. 2020 Jul;126(1):97-103
pubmed: 32124525
Epidemiol Infect. 2016 Jun;144(8):1784-91
pubmed: 26645476
Lancet Infect Dis. 2022 Oct;22(10):1465-1471
pubmed: 35839791
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
BJU Int. 2020 Sep;126 Suppl 1:33-37
pubmed: 32463977
Oncotarget. 2017 Apr 4;8(14):23322-23336
pubmed: 28177897
Eur Urol Oncol. 2021 Dec;4(6):904-913
pubmed: 33478936
J Urol. 2021 Mar;205(3):653-663
pubmed: 33026903
Eur Urol. 2019 Apr;75(4):570-578
pubmed: 30477981
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724